The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma

Gynecologic Oncology

Volumn 121, Issue 1, 2011, Pages 218-223

  Bishop, Erin A ^a,b   Lengyel, Ernst R ^a   Yamada, S Diane ^a   Montag, Anthony ^a   Temkin, Sarah M ^a,c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

c Met; HGF; Uterine serous carcinoma

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHI SQUARE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METASTASIS; MITOGENESIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STUDENT T TEST; TISSUE MICROARRAY; UTERUS CARCINOMA; UTERUS SEROUS CARCINOMA;

AGED; CYSTADENOCARCINOMA, SEROUS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; UTERINE NEOPLASMS;

EID: 79952814060     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.11.031     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007;57:43-66.
2. Hoskins WJ, Perez C, Young RC, Barakat R, Markman M, Randall M. Principles and Practice of Gynecologic Oncology. Fourth ed. Philadelphia: Lipincott Williams & Wilkins; 2005.
3. Macwhinnie N, Monaghan H. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer 2004;14(5):938-46. (Pubitemid 39238183)
4. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer 2004;90(9):1814-24. (Pubitemid 38725659)
5. Umpierre SA, Burke TW, Tornos C, Ordonez N, Levenback C, Morris M. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol 1994;13(2):127-30. (Pubitemid 24093834)
6. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11(18):6422-30. (Pubitemid 41338978)
7. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4(12):915-25. (Pubitemid 37493640)
8. Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med 2007;7(1):77-84. (Pubitemid 46322280)
9. Gentile A, Trusolino L, Comoglio P. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008;27(1):85-94.
10. Gheradi E, Sharpe M, Lane K, Sirulnik A, Stoker M. Hepatocyte growth factor/ scatter factor (HGF/SF), the c-Met receptor and the behavior of epithelial cells. Symp Soc Exp Biol 1993;47:163-81.
11. Weidner KM, Hartmann G, Naldini L, Comoglio PM, Sachs M, Fonatsch C, et al. Molecular characteristics of HGF-SF and its role in cell motility and invasion. EXS 1993;65:311-28.
12. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995;55(5):1129-38.
13. Scarpino S, Stoppacciaro A, Colarossi C, Cancellario F, Marzullo A, MarchesiM, et al. Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid. J Pathol 1999;189(4):570-5.
14. Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999;155(2):517-26. (Pubitemid 29370401)
15. Wong AST, Roskelley CD, Pelech S, Miller D, Leung PCK, Auersperg N. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res 2004;299(1):248-56. (Pubitemid 39078399)
16. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67(4): 1670-9. (Pubitemid 46383393)
17. Ayhan A, Ertunc D, Tok EC, Ayhan A. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer 2005;15(4): 618-23. (Pubitemid 41022899)
18. Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, et al. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 2003;288(2):382-9. (Pubitemid 36959954)
19. Wagatsuma S, Konno R, Sato S, Yajima A. Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 1998;82(3):520-30. (Pubitemid 28112991)
20. Takeuchi H, Bilchik A, Saha S, Umetani N, Mori T, Bilchik A, et al. c-MET expression in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003;9:1480-8. (Pubitemid 36418405)
21. van der Voort R, Taher T, Keehnen R, Smit L, Groenink M, Pals ST, et al. Paracrine regulation of germinal center B cell adhesion through the c-Met-hepatocyte growth factor/scatter factor pathway. J Exp Med 1997;185(12):2121-31. (Pubitemid 27265996)
22. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113(4):678-82. (Pubitemid 40038747)
23. Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, et al. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology 2007;51(1):54-62. (Pubitemid 46976378)
24. Bae-Jump V, Segreti EM, Vandermolen D, Kauma S. Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro. Gynecol Oncol 1999;73(2):265-72. (Pubitemid 29215742)
25. Sowter HM, Corps AN, Smith SK. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int J Cancer 1999;83(4):476-80. (Pubitemid 29489861)
26. McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 2007;106(1):16-22. (Pubitemid 46898605)
27. Zillhardt M, Christensen J, Lengyel E. An orally available small molecule inhibitor of c-Met, PF-2341066, reduces tumor burden in a pre-clinical model of ovarian cancer metastasis. Neoplasia 2010;12(1):1-10.